Analysts expect that Neon Therapeutics Inc (NASDAQ:NTGN) will report earnings of ($0.61) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Neon Therapeutics’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.46). Neon Therapeutics posted earnings of ($0.67) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The company is expected to issue its next earnings report on Monday, November 11th.
On average, analysts expect that Neon Therapeutics will report full-year earnings of ($2.51) per share for the current year, with EPS estimates ranging from ($3.18) to ($1.85). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.28) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01).
Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. bought a new stake in Neon Therapeutics in the first quarter worth $49,000. Westfield Capital Management Co. LP bought a new stake in Neon Therapeutics in the second quarter worth $149,000. Morgan Stanley increased its position in Neon Therapeutics by 10.8% in the second quarter. Morgan Stanley now owns 40,522 shares of the company’s stock worth $192,000 after purchasing an additional 3,939 shares during the last quarter. Bank of New York Mellon Corp increased its position in Neon Therapeutics by 112.1% in the second quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock worth $339,000 after purchasing an additional 37,755 shares during the last quarter. Finally, Northern Trust Corp increased its position in Neon Therapeutics by 8.5% in the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock worth $789,000 after purchasing an additional 12,971 shares during the last quarter. Institutional investors own 67.10% of the company’s stock.
Neon Therapeutics stock opened at $2.19 on Friday. The company has a current ratio of 6.13, a quick ratio of 6.13 and a debt-to-equity ratio of 0.12. Neon Therapeutics has a 1 year low of $1.61 and a 1 year high of $8.85. The firm’s 50 day moving average price is $2.29 and its 200-day moving average price is $4.04.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Recommended Story: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.